Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3HP-2827 in FGFR2-altered solid tumors
NCT06378593Phase 2Recruiting
- Sponsor
- 3H Pharmaceuticals
- Start
- Jun 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 3HP-2827 in solid tumor, sponsored by 3H Pharmaceuticals. Started Jun 2024; status: recruiting.
02
Drugs
3HP-2827
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06378593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378593.